Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study

Fig. 3

Individual growth curves over time for the 6 patients who met the primary endpoint (12-month survival). ADA = time at anti-drug antibody detection. *Due to the window of time associated with scheduled assessments, no weight was collected at 12 months for patient 05–001; therefore, the next available weight data point was used to graph the weight at 12 months; this patient died at age 15 months

Back to article page